Fredric E. Wondisford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fredric E. Wondisford has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Ronald N. Cohen
2 shared publications- Tania Maria Ortiga-Carvalho
Instituto de Biofísica Carlos Chagas Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil
2 shared publications Amisra Nikrodhanond
Department of Medicine and Committee on Molecular Metabolism and Nutrition, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA. 2Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 3Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan. 4Department of Pediatrics and the Committee on Genetics, The University of Chicago, Chicago, Illinois, USA
1 shared publicationAniket R. Sidhaye
Departments of Paediatrics and Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, CMSC 10-113, Baltimore, MD 21287, USA
1 shared publicationDanielle S. Machado
Department of Medicine and Committee on Molecular Metabolism and Nutrition, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA. 2Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 3Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan. 4Department of Pediatrics and the Committee on Genetics, The University of Chicago, Chicago, Illinois, USA
1 shared publicationDelia L. Porras
Departments of Pediatrics and Medicine, Metabolism Division, Johns Hopkins University, Baltimore, Maryland,1 Department of Medicine, Section of Endocrinology, University of Chicago Hospital, Chicago, Illinois2
1 shared publication
Latest Publications
- Open Access
- 1 June 2015
- Published by The Endocrine Society in Endocrinology
- Vol. 156 (6) , 1939-1940
A Direct Role for Thyroid Hormone in Development of the Adrenal Cortex
A relationship between thyroid and adrenal dysfunction has been recognized for some time. Certain human autoimmune conditions, for example, can destroy both the
- 1 June 2015
- Published by The Endocrine Society in Endocrinology
- Vol. 156 (6) , 1939-1940
Open AccessA Direct Role for Thyroid Hormone in Development of the Adrenal Cortex
A relationship between thyroid and adrenal dysfunction has been recognized for some time. Certain human autoimmune conditions, for example, can destroy both the
- Top Cited Papers
- 19 August 2014
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 10 (10) , 582-591
Thyroid hormone receptors and resistance to thyroid hormone disorders
The main isoforms of thyroid hormone receptors, THRα1, THRβ1 and THRβ2, are predominantly responsible for mediating thyroid hormone action, which is critical for normal development, growth and metabolism Patients with mutations in either THRA or THRB have been described and have strikingly different clinical phenotypes known as resistance to thyroid hormone (RTH)α and RTHβ, respectively Patients with RTHβ frequently present with elevated thyroid hormone levels, normal or elevated TSH levels and goitre, which suggests a critical role for THRB in negative-feedback regulation Currently only seven patients with RTHα have been described; these individuals have near-normal levels of thyroid hormones and TSH but display hypothyroidism, delayed growth and constipation Studies of mutations associated with RTH disorders using transgenic mouse models have provided novel insights into the divergent roles of THRA and THRB in physiology
- 19 August 2014
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 10 (10) , 582-591
Top Cited PapersThyroid hormone receptors and resistance to thyroid hormone disorders
The main isoforms of thyroid hormone receptors, THRα1, THRβ1 and THRβ2, are predominantly responsible for mediating thyroid hormone action, which is critical for normal development, growth and metabolism Patients with mutations in either THRA or THRB have been described and have strikingly different clinical phenotypes known as resistance to thyroid hormone (RTH)α and RTHβ, respectively Patients with RTHβ frequently present with elevated thyroid hormone levels, normal or elevated TSH levels and goitre, which suggests a critical role for THRB in negative-feedback regulation Currently only seven patients with RTHα have been described; these individuals have near-normal levels of thyroid hormones and TSH but display hypothyroidism, delayed growth and constipation Studies of mutations associated with RTH disorders using transgenic mouse models have provided novel insights into the divergent roles of THRA and THRB in physiology
- Open Access
- 1 December 2011
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (12) , 4621-4623
A new medical therapy for Cushing disease?
Members of the ErbB family of cell surface tyrosine kinase receptors are important targets for cancer treatment because they frequently contribute to the pathogenesis of malignancy. In this issue of the JCI, Fukuoka et al. generate data that suggest that using a tyrosine kinase inhibitor (TKI) against epidermal growth factor receptor (EGFR; also known as ErbB1) may be a novel approach for treating patients with hypercortisolemia due to pituitary corticotroph adenomas (Cushing disease). While surgical resection remains the cornerstone of treatment for individuals with such tumors, this study suggests that TKIs could perhaps be used to reduce tumor size prior to surgery or to treat recurrent disease after surgery.
- 1 December 2011
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (12) , 4621-4623
Open AccessA new medical therapy for Cushing disease?
Members of the ErbB family of cell surface tyrosine kinase receptors are important targets for cancer treatment because they frequently contribute to the pathogenesis of malignancy. In this issue of the JCI, Fukuoka et al. generate data that suggest that using a tyrosine kinase inhibitor (TKI) against epidermal growth factor receptor (EGFR; also known as ErbB1) may be a novel approach for treating patients with hypercortisolemia due to pituitary corticotroph adenomas (Cushing disease). While surgical resection remains the cornerstone of treatment for individuals with such tumors, this study suggests that TKIs could perhaps be used to reduce tumor size prior to surgery or to treat recurrent disease after surgery.
- 1 October 2006
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (20) , 7747-7759
Increased Pancreatic β-Cell Proliferation Mediated by CREB Binding Protein Gene Activation
The cyclic AMP (cAMP) signaling pathway is central in beta-cell gene expression and function. In the nucleus, protein kinase A (PKA) phosphorylates CREB, resulting in recruitment of the transcriptional coactivators p300 and CREB binding protein (CBP). CBP, but not p300, is phosphorylated at serine 436 in response to insulin action. CBP phosphorylation disrupts CREB-CBP interaction and thus reduces nuclear cAMP action. To elucidate the importance of the cAMP-PKA-CREB-CBP pathway in pancreatic beta cells specifically at the nuclear level, we have examined mutant mice lacking the insulin-dependent phosphorylation site of CBP. In these mice, the CREB-CBP interaction is enhanced in both the absence and presence of cAMP stimulation. We found that islet and beta-cell masses were increased twofold, while pancreas weights were not different from the weights of wild-type littermates. beta-Cell proliferation was increased both in vivo and in vitro in isolated islet cultures. Surprisingly, glucose-stimulated insulin secretion from perfused, isolated mutant islets was reduced. However, beta-cell depolarization with KCl induced similar levels of insulin release from mutant and wild-type islets, indicating normal insulin synthesis and storage. In addition, transcripts of pgc1a, which disrupts glucose-stimulated insulin secretion, were also markedly elevated. In conclusion, sustained activation of CBP-responsive genes results in increased beta-cell proliferation. In these beta cells, however, glucose-stimulated insulin secretion was diminished, resulting from concomitant CREB-CBP-mediated pgc1a gene activation.
- 1 October 2006
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (20) , 7747-7759
Increased Pancreatic β-Cell Proliferation Mediated by CREB Binding Protein Gene Activation
The cyclic AMP (cAMP) signaling pathway is central in beta-cell gene expression and function. In the nucleus, protein kinase A (PKA) phosphorylates CREB, resulting in recruitment of the transcriptional coactivators p300 and CREB binding protein (CBP). CBP, but not p300, is phosphorylated at serine 436 in response to insulin action. CBP phosphorylation disrupts CREB-CBP interaction and thus reduces nuclear cAMP action. To elucidate the importance of the cAMP-PKA-CREB-CBP pathway in pancreatic beta cells specifically at the nuclear level, we have examined mutant mice lacking the insulin-dependent phosphorylation site of CBP. In these mice, the CREB-CBP interaction is enhanced in both the absence and presence of cAMP stimulation. We found that islet and beta-cell masses were increased twofold, while pancreas weights were not different from the weights of wild-type littermates. beta-Cell proliferation was increased both in vivo and in vitro in isolated islet cultures. Surprisingly, glucose-stimulated insulin secretion from perfused, isolated mutant islets was reduced. However, beta-cell depolarization with KCl induced similar levels of insulin release from mutant and wild-type islets, indicating normal insulin synthesis and storage. In addition, transcripts of pgc1a, which disrupts glucose-stimulated insulin secretion, were also markedly elevated. In conclusion, sustained activation of CBP-responsive genes results in increased beta-cell proliferation. In these beta cells, however, glucose-stimulated insulin secretion was diminished, resulting from concomitant CREB-CBP-mediated pgc1a gene activation.
- 28 February 2006
- Published by Elsevier in Cell Metabolism
- Vol. 3 (2) , 81-82
Unlikely partners in weight loss?
- 28 February 2006
- Published by Elsevier in Cell Metabolism
- Vol. 3 (2) , 81-82
Unlikely partners in weight loss?
- Open Access
- 1 January 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (1) , 295-302
Cross-talk between Thyroid Hormone Receptor and Liver X Receptor Regulatory Pathways Is Revealed in a Thyroid Hormone Resistance Mouse Model
- 1 January 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (1) , 295-302
Open AccessCross-talk between Thyroid Hormone Receptor and Liver X Receptor Regulatory Pathways Is Revealed in a Thyroid Hormone Resistance Mouse Model
- Open Access
- 1 September 2005
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 115 (9) , 2517-2523
Negative regulation by thyroid hormone receptor requires an intact coactivator-binding surface
Thyroid hormone (TH) action is mediated by TH receptors (TRs), which are members of the nuclear hormone receptor superfamily. In vitro studies have demonstrated that TR activity is regulated by interactions with corepressor and coactivator proteins (CoRs and CoAs, respectively). TH stimulation is thought to involve dissociation of CoRs and recruitment of CoAs to the liganded TR. In contrast, negative regulation by TH is thought to occur via recruitment of CoRs to the liganded TR. The physiological role of CoAs bound to TRs, however, has yet to be defined. In this study, we used gene-targeting techniques to mutate the TR-β locus within its activation function–2 (AF-2) domain (E457A). This mutation was chosen because it completely abolished CoA recruitment in vitro, while preserving normal triiodothyronine (T3) binding and CoR interactions. As expected, TH-stimulated gene expression was reduced in homozygous E457A mice. However, these animals also displayed abnormal regulation of the hypothalamic-pituitary-thyroid axis. Serum thyroxine, T3, and thyroid-stimulating hormone (TSH) levels and pituitary Tshb mRNA levels were inappropriately elevated compared with those of WT animals, and L-T3 treatment failed to suppress serum TSH and pituitary Tshb mRNA levels. Therefore, the AF-2 domain of TR-β is required for positive and, paradoxically, for negative regulation by TH in vivo.
- 1 September 2005
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 115 (9) , 2517-2523
Open AccessNegative regulation by thyroid hormone receptor requires an intact coactivator-binding surface
Thyroid hormone (TH) action is mediated by TH receptors (TRs), which are members of the nuclear hormone receptor superfamily. In vitro studies have demonstrated that TR activity is regulated by interactions with corepressor and coactivator proteins (CoRs and CoAs, respectively). TH stimulation is thought to involve dissociation of CoRs and recruitment of CoAs to the liganded TR. In contrast, negative regulation by TH is thought to occur via recruitment of CoRs to the liganded TR. The physiological role of CoAs bound to TRs, however, has yet to be defined. In this study, we used gene-targeting techniques to mutate the TR-β locus within its activation function–2 (AF-2) domain (E457A). This mutation was chosen because it completely abolished CoA recruitment in vitro, while preserving normal triiodothyronine (T3) binding and CoR interactions. As expected, TH-stimulated gene expression was reduced in homozygous E457A mice. However, these animals also displayed abnormal regulation of the hypothalamic-pituitary-thyroid axis. Serum thyroxine, T3, and thyroid-stimulating hormone (TSH) levels and pituitary Tshb mRNA levels were inappropriately elevated compared with those of WT animals, and L-T3 treatment failed to suppress serum TSH and pituitary Tshb mRNA levels. Therefore, the AF-2 domain of TR-β is required for positive and, paradoxically, for negative regulation by TH in vivo.